Hurley Capital LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Hurley Capital LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,215 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

Several other large investors have also modified their holdings of the stock. United Bank grew its holdings in Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Pfizer by 0.5% in the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock valued at $15,348,000 after purchasing an additional 2,600 shares in the last quarter. Royal London Asset Management Ltd. raised its position in Pfizer by 2.7% in the third quarter. Royal London Asset Management Ltd. now owns 2,393,288 shares of the biopharmaceutical company’s stock valued at $69,262,000 after purchasing an additional 63,687 shares during the period. Quarry LP lifted its position in shares of Pfizer by 1,397.9% during the third quarter. Quarry LP now owns 16,462 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 15,363 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in Pfizer by 32.1% during the 3rd quarter. Quantinno Capital Management LP now owns 369,789 shares of the biopharmaceutical company’s stock valued at $10,702,000 after purchasing an additional 89,835 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on PFE shares. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Pfizer stock opened at $22.99 on Friday. The business has a 50 day simple moving average of $25.87 and a 200 day simple moving average of $26.76. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $130.39 billion, a PE ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $22.95 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the firm posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.